MediciNova Wins Contract Research and Development Innovation Award for MN-166 Treatment for Neurological Diseases
ByAinvest
Thursday, Nov 6, 2025 6:02 pm ET1min read
MNOV--
MediciNova has won the Contract Research and Development Innovation Award at the 2025 BioTech Breakthrough Awards for its work on MN-166 (ibudilast), a drug candidate for neurological diseases like ALS. The award recognizes MediciNova's innovative approach to developing disease-modifying therapies for conditions with few treatment options. The company's ongoing Phase 2/3 COMBAT-ALS trial of MN-166 in ALS patients is a key part of its mission to deliver meaningful breakthroughs for patients.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet